Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

This multinational, randomized, double-blind trial, (ClinicalTrials.gov identifier NCT02149121) was designed to demonstrate equivalence in pharmacokinetics and efficacy between CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA). Adults with active RA were treated with CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won, Božić-Majstorović, Ljubinka, Milakovic, Dragana, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Molina, Francisco Fidencio Cons, Shesternya, Pavel, Miranda, Pedro, Medina-Rodriguez, Francisco G., Wiland, Piotr, Jeka, Slawomir, Chavez-Corrales, Jose, Garmish, Olena, Linde, Thomas, Rekalov, Dmytro, Hrycaj, Pawel, Krause, Andreas, Fomina, Natalia, Piura, Olena, Abello-Banfi, Mauricio, Suh, Chang-Hee, Shim, Seung Cheol, Lee, Sang Joon, Lee, Sung Young, Kim, Sung Hwan, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152436/
https://www.ncbi.nlm.nih.gov/pubmed/30010481
http://dx.doi.org/10.1080/19420862.2018.1487912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152436/
https://www.ncbi.nlm.nih.gov/pubmed/30010481
http://dx.doi.org/10.1080/19420862.2018.1487912

Ejemplares similares